Ourania Tatsis - 14 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
14 Feb 2023
Net transactions value
-$95,527
Form type
4
Filing time
16 Feb 2023, 15:18:26 UTC
Previous filing
14 Feb 2023
Next filing
22 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $21,008 -71 -0.11% $295.89 65,694 14 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $5,930 -20 -0.03% $296.48 65,674 14 Feb 2023 Direct F1
transaction VRTX Common Stock Sale $12,813 -43 -0.07% $297.98 65,631 14 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $40,446 -135 -0.21% $299.60 65,496 14 Feb 2023 Direct F1, F2, F5
transaction VRTX Common Stock Sale $15,330 -51 -0.08% $300.58 65,445 14 Feb 2023 Direct F1, F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.36 to $296.32).
F4 Open market sales reported on this line occurred at a weighted average price of $297.98 (range $297.50 to $298.48).
F5 Open market sales reported on this line occurred at a weighted average price of $299.60 (range $299.19 to $300.16).
F6 Open market sales reported on this line occurred at a weighted average price of $300.58 (range $300.34 to $301.01).